| abstract |
Disclosed are compounds represented by the general formula (I), wherein each symbol is as defined in the specification. The compounds bind specifically to DP receptors and antagonize the same, but only weakly bind to other prostaglandin receptors, enabling the production of drugs having few side effects. They are useful in preventing and/or treating allergic diseases including allergic nephritis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergies; systemic mast cell disease; systemic mast cell activation disorder; anaphylactic shock; airway contraction; urticaria; eczema; diseases associated with itching including atopic dermatitis; inflammation; chronic obstructive pulmonary disease, ischemic reperfusion injury; cerebrovascular disorders; rheumatoid arthritis; pleuritis and ulcerative colitis. |